Screening tool for fatty liver disease using body impedance measurement
Tests a body impedance scan to help spot fatty liver disease in adults.
Plain-language title generated from the registry record
Registry title: Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Key facts
- Where
- London, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04873258, who can take part
Where in United Kingdom
- Richmond Pharmacology Ltd. 1a Newcomen St, London BridgeLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Richmond Research Institute
- Trial code
- NCT04873258
- Record updated
- 19 August 2026
- Original description
A generic screening study to establish structural and/or functional baselines of specific organs.Read full original descriptionShow less
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis
A generic screening study to establish structural and/or functional baselines of specific organs.
Inclusion: Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent; Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations; An understanding, ability and willingness to fully comply with project procedures and restrictions; For PART B only:; With a known history of MASLD as evidenced either of:; GP diagnosis on HCF; Documented Fibroscan or liver US demonstrating MASLD.
Exclusion: Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease); Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other); An Implanted cardiac devices; Alcohol consumption >30 units per week.